35 Participants Needed

At-Home Urine Test for Ectopic Pregnancy

(CONNECT Trial)

LA
JP
Overseen ByJocelyn Phipers, NP
Age: 18 - 65
Sex: Female
Trial Phase: Academic
Sponsor: University of Colorado, Denver
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

The goal of this pilot study is to assess the accuracy and precision of an at-home quantitative urine beta hCG (b-hCG) test in the management of pregnancy of unknown location (PUL).

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. However, if you are using hormonal contraception, you must have stopped it at least 3 months before participating.

What data supports the effectiveness of the at-home quantitative urine b-hCG test for detecting ectopic pregnancy?

Research shows that urine tests for human chorionic gonadotropin (hCG) can be practical and efficient for screening ectopic pregnancies, with one study noting an 80% efficiency rate for a urine hCG tube test. Although blood tests are more accurate, urine tests are easier, cheaper, and faster, making them a useful tool for initial screening.12345

Is the at-home urine test for ectopic pregnancy safe for humans?

The studies reviewed focus on the accuracy and sensitivity of urine tests for detecting pregnancy hormones, but they do not report any safety concerns for humans using these tests.46789

How does the at-home urine test for ectopic pregnancy differ from other treatments?

The at-home urine test for ectopic pregnancy is unique because it allows for the detection of the pregnancy hormone hCG (human chorionic gonadotropin) directly from urine at home, offering a convenient and non-invasive alternative to blood tests, which are typically more reliable but require a visit to a healthcare provider.2351011

Eligibility Criteria

The MIRA CONNECT Study is for individuals who are not pregnant (as controls) or have been diagnosed with a pregnancy of unknown location (PUL) needing regular monitoring. It excludes those on recent hormonal contraception, with very high initial hCG levels, night shift workers, diabetes patients, unstable patients at risk of ruptured ectopic pregnancy, those with renal disease or any cancer including hCG-secreting tumors.

Inclusion Criteria

Non-pregnant (controls)
I am being monitored for PUL with regular hCG blood tests.

Exclusion Criteria

Use of hormonal contraception within last 3 months (controls)
Initial serum hCG level > 100,000 mIU/ml (cases)
Patients who work the night shift (controls)
See 5 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Initial Diagnosis and Setup

Initial diagnosis of pregnancy of unknown location and setup of Mira device

1 day
1 visit (in-person)

Testing Phase

Participants perform daily urine and serum hCG testing for 7 days

7 days
7 visits (in-person for serum testing), daily at-home urine testing

Follow-up

Participants are monitored for safety and effectiveness after testing phase

2 weeks

Treatment Details

Interventions

  • At-home quantitative urine b-hCG test
Trial OverviewThis pilot study tests the accuracy and precision of an at-home urine test that measures beta hCG levels for managing pregnancies where the location is unknown. The aim is to see if this method can reliably monitor these conditions without frequent hospital visits.
Participant Groups
2Treatment groups
Active Control
Placebo Group
Group I: PUL: Pregnancy unknown location diagnosisActive Control1 Intervention
Pregnant patients with unknown location diagnosis will use the pregnancy test device
Group II: CNTRL: Non-pregnant control patientsPlacebo Group1 Intervention
Non-pregnant patients will use the pregnancy test device

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Colorado, Denver

Lead Sponsor

Trials
1,842
Recruited
3,028,000+

Findings from Research

In a study of 80 women, urine hCG levels were found to be well correlated with serum hCG levels, especially after correcting for creatinine, suggesting urine tests could be a convenient alternative for monitoring pregnancy outcomes.
While serum hCG measurements are more reliable for predicting pregnancy outcomes in cases of unknown location, urine hCG tests may still help identify low-risk cases, indicating their potential role in clinical decision-making.
The potential use of urinary hCG measurements in the management of pregnancies of unknown location.Bobdiwala, S., Harvey, R., Abdallah, Y., et al.[2022]
The study established that an immunomagnetic reduction (IMR) assay can accurately measure total hCGβ concentrations in urine, showing a strong correlation with serum levels, which could provide a non-invasive alternative for diagnosing ectopic pregnancy.
With a calibration curve ranging from 0.01 ng/mL to 10,000 ng/mL and excellent correlation coefficients (R(2)=0.994 for urine vs serum), the IMR assay demonstrates potential for point-of-care testing in clinical settings.
Quantitative analysis of total β-subunit of human chorionic gonadotropin concentration in urine by immunomagnetic reduction to assist in the diagnosis of ectopic pregnancy.Chen, CY., Hwu, YM., Chen, CP., et al.[2018]
In a study of 51 patients with suspected ectopic pregnancy, serum hCG measurements were found to be the most accurate test for diagnosis, with an efficiency of 86%.
The urinary hCG tube test, while slightly less accurate at 80%, is recommended as a practical screening tool due to its ease of use, low cost, and quick results.
Predictive value analysis of measurements of human chorionic gonadotropin, pregnancy specific beta 1-glycoprotein, placental lactogen, and cystine aminopeptidase for the diagnosis of ectopic pregnancy.Braunstein, GD., Asch, RH.[2019]

References

The potential use of urinary hCG measurements in the management of pregnancies of unknown location. [2022]
Quantitative analysis of total β-subunit of human chorionic gonadotropin concentration in urine by immunomagnetic reduction to assist in the diagnosis of ectopic pregnancy. [2018]
Predictive value analysis of measurements of human chorionic gonadotropin, pregnancy specific beta 1-glycoprotein, placental lactogen, and cystine aminopeptidase for the diagnosis of ectopic pregnancy. [2019]
A sensitive bedside urine test for human chorionic gonadotrophin in suspected ectopic pregnancy. [2014]
Blood or urine measurement of human chorionic gonadotropin for detection of ectopic pregnancy? A comparative study of quantitative and qualitative methods in both fluids. [2009]
Comparison of accuracy and certainty of results of six home pregnancy tests available over-the-counter. [2008]
A commercial pregnancy test modified for field studies of fetal loss. [2019]
Performance of qualitative urinary hCG assays. [2016]
The need for a quantitative urine hCG assay. [2009]
Assay of human chorionic gonadotrophin in the patient with a suspected ectopic pregnancy. [2014]
11.United Statespubmed.ncbi.nlm.nih.gov
A sensitive urine pregnancy test as an aid in the diagnosis of ectopic pregnancy. [2019]